Your browser doesn't support javascript.
Prevalence of adverse drug reactions associated with emergency department visits and risk factors for hospitalization
Farmacia Hospitalaria ; 47(1):20-25, 2023.
Artículo en Inglés, Español | EMBASE | ID: covidwho-2292560
ABSTRACT

Objective:

Adverse drug reactions increase morbidity and mortality, prolong hospital stay and increase healthcare costs. The primary objective of this study was to determine the prevalence of emergency department visits for adverse drug reactions and to describe their characteristics. The secondary objective was to determine the predictor variables of hospitalization for adverse drug reactions associated with emergency department visits. Method(s) Observational and retrospective study of adverse drug reactions registered in an emergency department, carried out from November 15th to December 15th, 2021. The demographic and clinical characteristics of the patients, the drugs involved and the adverse drug reactions were described. Logistic regression was performed to identify factors related to hospitalization for adverse drug reactions. Result(s) 10,799 patients visited the emergency department and 216 (2%) patients with adverse drug reactions were included. The mean age was 70 +/- 17.5 (18-98) years and 47.7% of the patients were male. A total of 54.6% of patients required hospitalization and 1.6% died from adverse drug reactions. The total number of drugs involved was 315 with 149 different drugs. The pharmacological group corresponding to the nervous system constituted the most representative group (n = 81). High-risk medications, such as antithrombotic agents (n = 53), were the subgroup of medications that caused the most emergency department visits and hospitalization. Acenocumarol (n = 20) was the main drug involved. Gastrointestinal (n = 62) disorders were the most common. Diarrhea (n = 16) was the most frequent adverse drug reaction, while gastrointestinal bleeding (n = 13) caused the highest number of hospitalizations. Charlson comorbidity index behaved as an independent risk factor for hospitalization (aOR 3.24, 95% CI 1.47-7.13, p = 0.003, in Charlson comorbidity index 4-6;and aOR 20.07, 95% CI 6.87-58.64, p = 0.000, in Charlson comorbidity index >= 10). Conclusion(s) The prevalence of emergency department visits for adverse drug reactions continues to be a non-negligible health problem. High-risk drugs such as antithrombotic agents were the main therapeutic subgroup involved. Charlson comorbidity index was an independent factor in hospitalization, while gastrointestinal bleeding was the adverse drug reaction with the highest number of hospital admissions.Copyright © 2022 Sociedad Espanola de Farmacia Hospitalaria (S.E.F.H)
Palabras clave
Adverse drug reactions; Antithrombotic agents; Emergency department; Gastrointestinal disorders; Hospitalization; adult; aged; all cause mortality; anemia; article; Barthel index; causality; Charlson Comorbidity Index; clinical feature; comorbidity; connective tissue disease/si [Side Effect]; coronavirus disease 2019/dt [Drug Therapy]; coronavirus disease 2019/pc [Prevention]; demographics; diarrhea/si [Side Effect]; drug fatality/si [Side Effect]; emergency ward; endocrine disease/si [Side Effect]; female; frailty; gastrointestinal disease/si [Side Effect]; gastrointestinal hemorrhage/si [Side Effect]; heart disease/si [Side Effect]; hematologic disease/si [Side Effect]; hepatobiliary disease/si [Side Effect]; hospital admission; hospital discharge; hospital readmission; human; immunopathology/si [Side Effect]; in-hospital mortality; infection/si [Side Effect]; infestation/si [Side Effect]; international normalized ratio; kidney disease/si [Side Effect]; length of stay; lymphatic system disease/si [Side Effect]; major clinical study; male; mediastinum disease/si [Side Effect]; Medical Dictionary for Regulatory Activities; mental disease/si [Side Effect]; metabolic disorder/si [Side Effect]; musculoskeletal disease/si [Side Effect]; neurologic disease/si [Side Effect]; neutropenic enterocolitis/si [Side Effect]; nutritional disorder/si [Side Effect]; observational study; patient triage; predictor variable; prevalence; respiratory tract disease/si [Side Effect]; retrospective study; risk factor; side effect/si [Side Effect]; skin disease/si [Side Effect]; social problem; subdural hematoma/si [Side Effect]; tertiary care center; thorax disease/si [Side Effect]; university hospital; urinary tract disease/si [Side Effect]; vaccination; vascular disease/si [Side Effect]; acenocoumarol/ae [Adverse Drug Reaction]; acenocoumarol/pv [Special Situation for Pharmacovigilance]; alkylating agent/ae [Adverse Drug Reaction]; alkylating agent/pv [Special Situation for Pharmacovigilance]; antibiotic agent/ae [Adverse Drug Reaction]; antibiotic agent/pv [Special Situation for Pharmacovigilance]; anticoagulant agent/ae [Adverse Drug Reaction]; anticoagulant agent/pv [Special Situation for Pharmacovigilance]; anticonvulsive agent/ae [Adverse Drug Reaction]; anticonvulsive agent/pv [Special Situation for Pharmacovigilance]; antidepressant agent/ae [Adverse Drug Reaction]; antidepressant agent/pv [Special Situation for Pharmacovigilance]; antineoplastic antimetabolite/ae [Adverse Drug Reaction]; antineoplastic antimetabolite/pv [Special Situation for Pharmacovigilance]; antineoplastic monoclonal antibody/ae [Adverse Drug Reaction]; antineoplastic monoclonal antibody/pv [Special Situation for Pharmacovigilance]; antithrombocytic agent/ae [Adverse Drug Reaction]; antithrombocytic agent/pv [Special Situation for Pharmacovigilance]; antivitamin K/ae [Adverse Drug Reaction]; antivitamin K/pv [Special Situation for Pharmacovigilance]; anxiolytic agent/ae [Adverse Drug Reaction]; anxiolytic agent/pv [Special Situation for Pharmacovigilance]; beta adrenergic receptor blocking agent/ae [Adverse Drug Reaction]; beta adrenergic receptor blocking agent/pv [Special Situation for Pharmacovigilance]; bleomycin/ae [Adverse Drug Reaction]; bleomycin/pv [Special Situation for Pharmacovigilance]; cisplatin/ae [Adverse Drug Reaction]; cisplatin/pv [Special Situation for Pharmacovigilance]; corticosteroid derivative/ae [Adverse Drug Reaction]; corticosteroid derivative/pv [Special Situation for Pharmacovigilance]; dexamethasone/ae [Adverse Drug Reaction]; dexamethasone/pv [Special Situation for Pharmacovigilance]; edoxaban/ae [Adverse Drug Reaction]; edoxaban/pv [Special Situation for Pharmacovigilance]; etoposide/ae [Adverse Drug Reaction]; etoposide/pv [Special Situation for Pharmacovigilance]; fentanyl/ae [Adverse Drug Reaction]; fentanyl/pv [Special Situation for Pharmacovigilance]; furosemide/ae [Adverse Drug Reaction]; furosemide/pv [Special Situation for Pharmacovigilance]; immunosuppressive agent/ae [Adverse Drug Reaction]; immunosuppressive agent/pv [Special Situation for Pharmacovigilance]; insulin derivative/ae [Adverse Drug Reaction]; insulin derivative/pv [Special Situation for Pharmacovigilance]; laxative/ae [Adverse Drug Reaction]; laxative/pv [Special Situation for Pharmacovigilance]; loop diuretic agent/ae [Adverse Drug Reaction]; loop diuretic agent/pv [Special Situation for Pharmacovigilance]; low molecular weight heparin/ae [Adverse Drug Reaction]; low molecular weight heparin/pv [Special Situation for Pharmacovigilance]; neuroleptic agent/ae [Adverse Drug Reaction]; neuroleptic agent/pv [Special Situation for Pharmacovigilance]; nonsteroid antiinflammatory agent/ae [Adverse Drug Reaction]; nonsteroid antiinflammatory agent/pv [Special Situation for Pharmacovigilance]; opiate derivative/ae [Adverse Drug Reaction]; opiate derivative/pv [Special Situation for Pharmacovigilance]; oral antidiabetic agent/ae [Adverse Drug Reaction]; oral antidiabetic agent/pv [Special Situation for Pharmacovigilance]; paclitaxel/ae [Adverse Drug Reaction]; paclitaxel/pv [Special Situation for Pharmacovigilance]; pembrolizumab/ae [Adverse Drug Reaction]; pembrolizumab/pv [Special Situation for Pharmacovigilance]; platinum derivative/ae [Adverse Drug Reaction]; platinum derivative/pv [Special Situation for Pharmacovigilance]; quetiapine/ae [Adverse Drug Reaction]; quetiapine/pv [Special Situation for Pharmacovigilance]; SARS-CoV-2 vaccine/ae [Adverse Drug Reaction]; SARS-CoV-2 vaccine/dt [Drug Therapy]; SARS-CoV-2 vaccine/pv [Special Situation for Pharmacovigilance]; tacrolimus/ae [Adverse Drug Reaction]; tacrolimus/pv [Special Situation for Pharmacovigilance]; taxane derivative/ae [Adverse Drug Reaction]; taxane derivative/pv [Special Situation for Pharmacovigilance]; thiazide diuretic agent/ae [Adverse Drug Reaction]; thiazide diuretic agent/pv [Special Situation for Pharmacovigilance]; Vinca alkaloid/ae [Adverse Drug Reaction]; Vinca alkaloid/pv [Special Situation for Pharmacovigilance]

Texto completo: Disponible Colección: Bases de datos de organismos internacionales Base de datos: EMBASE Tipo de estudio: Estudio observacional / Estudio pronóstico Idioma: Inglés / Español Revista: Farmacia Hospitalaria Año: 2023 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos de organismos internacionales Base de datos: EMBASE Tipo de estudio: Estudio observacional / Estudio pronóstico Idioma: Inglés / Español Revista: Farmacia Hospitalaria Año: 2023 Tipo del documento: Artículo